Evaluation of Tyrosine Kinase-2 (TYK2) signaling pathway gene expression and the presence of the single-nucleotide polymorphism rs12720356 in the peripheral blood of patients with severe psoriasis and loss of systemic treatment response
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Investigating psoriasis, this study found that multiple Tyrosine Kinase-2 (TYK2) pathway markers in Peripheral Blood Mononuclear Cells (PBMCs) are associated with a loss of treatment response in patients. Simultaneous marker evaluation shows promise for understanding psoriasis phenotypes.
Area Of Science
- Immunodermatology
- Molecular Biology
- Genetics
Background
- Psoriasis pathogenesis involves complex transcription processes.
- Understanding the link between these processes and specific patient phenotypes requires further research.
Purpose Of The Study
- To investigate the association between Peripheral Blood Mononuclear Cell (PBMC) endotypic profiles and treatment response loss in psoriasis patients.
- To identify specific molecular markers correlating with treatment outcomes.
Main Methods
- Gene expression of TYK2, IL-12, IL-23, IL-6, and TNF in PBMCs was quantified.
- Single-Nucleotide Polymorphisms (SNPs) were screened.
- Hierarchical clustering analyzed gene expression data from 178 psoriasis patients.
Main Results
- Tyrosine Kinase-2 (TYK2) was upregulated in patients with Psoriasis Area and Severity Index (PASI) > 10.
- A subset of 19 patients showed increased PASI and Dermatology Life Quality Index (DLQI) scores with upregulated TYK2-dependent mediators.
- Three patients carried the TYK2I684S variant.
Conclusions
- Single molecular markers have limited utility for psoriasis diagnosis due to variability.
- Simultaneous evaluation of multiple markers, particularly within the TYK2 pathway, shows promise for predicting treatment response.
- An association exists between multiple TYK2 pathway markers and loss of systemic treatment response in psoriasis.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...